PR inside: Hemogenyx Pharmaceuticals PLC Announces Half-year Financial Report
(PR-inside.com) Half-year Report
Interim Results for the period ended 30 June 2026
LONDON, UK / ACCESS Newswire / September 28, 2026 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the"Company") (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2026.
All financial amounts are stated in GBP British pounds unless otherwise indicated.
Key Highlights
Second Annual IND Report submitted to the FDA and encouraging results observed in the three adult patients treated at the first dose level. Trial ..
https://reports.pr-inside.com/hemogenyx ... 227949.htm
Copyright PR-Inside.com 2026
